Lilly and Incyte announce positive top-line results from phase III study (BREEZE-AD5) of baricitinib in patients with moderate- to severe atopic dermatitis

Study (n=440) designed for and conducted in North America evaluating efficacy and safety of 1mg and 2mg doses of baricitinib monotherapy reported that 2mg dose met primary endpoint of proportion of participants achieving EASI75 at week 16 (29.5% vs. 8.2% placebo; p<0.001).

SPS commentary:

Currently, baricitinib in combination with methotrexate, is licensed for reducing the signs and symptoms of moderate- to severe rheumatoid arthritis in adult patients who have responded inadequately to one or more disease-modifying anti-rheumatic drugs.

Biospace Inc.